Humacyte, Inc. (NASDAQ:HUMA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Humacyte, Inc. (NASDAQ:HUMA) has been assigned a consensus rating of “Moderate Buy” from the eight research firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $8.1429.

Several analysts have commented on the company. HC Wainwright reissued a “buy” rating and issued a $3.00 price objective on shares of Humacyte in a report on Monday, December 1st. BTIG Research reiterated a “buy” rating and set a $6.00 target price on shares of Humacyte in a research report on Monday, February 9th. Wall Street Zen cut shares of Humacyte from a “hold” rating to a “sell” rating in a research note on Sunday, December 21st. UBS Group reissued a “buy” rating on shares of Humacyte in a report on Monday, December 1st. Finally, D. Boral Capital restated a “buy” rating and set a $25.00 price objective on shares of Humacyte in a research report on Thursday, February 19th.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd boosted its holdings in Humacyte by 841.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 70,414 shares of the company’s stock worth $68,000 after buying an additional 62,931 shares during the last quarter. Aristides Capital LLC acquired a new position in shares of Humacyte during the fourth quarter valued at approximately $156,000. Virtu Financial LLC acquired a new position in shares of Humacyte during the fourth quarter valued at approximately $252,000. XTX Topco Ltd lifted its position in shares of Humacyte by 236.1% in the fourth quarter. XTX Topco Ltd now owns 650,858 shares of the company’s stock valued at $625,000 after acquiring an additional 457,236 shares in the last quarter. Finally, Quadrature Capital Ltd purchased a new position in shares of Humacyte in the fourth quarter valued at approximately $201,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Stock Performance

NASDAQ HUMA opened at $1.16 on Friday. The stock has a market capitalization of $217.23 million, a price-to-earnings ratio of -5.04 and a beta of 1.89. Humacyte has a twelve month low of $0.88 and a twelve month high of $3.36. The company has a current ratio of 1.62, a quick ratio of 0.90 and a debt-to-equity ratio of 2.97. The stock has a 50-day moving average of $1.09 and a 200 day moving average of $1.32.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.